TrialJAMA cardiology2026

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.

Sharon L Mulvagh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.